Envoy Medical Awarded Patent for Recharge System used with Implantable Battery
Envoy Medical (NASDAQ: COCH), a hearing health company specializing in fully implanted hearing systems, has been awarded a new patent (No. 12,081,061) for its Recharge System for Implantable Battery. The patent, issued on September 3rd, relates to predicting and managing the thermal dose during battery charging, ensuring safe temperatures for implanted rechargeable batteries.
This technology adjusts the current provided to the device during charging, maintaining safety for patients with implanted medical devices. CEO Brent Lucas emphasized the importance of this innovation in risk mitigation for implanted devices, stating it as an effective solution for their products. The patent adds to Envoy Medical's growing portfolio, furthering their mission to develop fully implanted devices for those with significant hearing loss.
Envoy Medical (NASDAQ: COCH), un'azienda specializzata nella salute uditiva e nei sistemi acustici completamente impiantati, ha ottenuto un nuovo brevetto (No. 12,081,061) per il suo Sistema di Ricarica per Batterie Impiantabili. Il brevetto, emesso il 3 settembre, riguarda la previsione e la gestione della dose termica durante la ricarica della batteria, garantendo temperature sicure per le batterie ricaricabili impiantate.
Questa tecnologia regola la corrente fornita al dispositivo durante la ricarica, mantenendo la sicurezza per i pazienti con dispositivi medici impiantati. Il CEO Brent Lucas ha sottolineato l'importanza di questa innovazione nella mitigazione dei rischi per i dispositivi impiantati, definendola una soluzione efficace per i loro prodotti. Il brevetto si aggiunge al crescente portafoglio di Envoy Medical, promuovendo ulteriormente la loro missione di sviluppare dispositivi completamente impiantati per coloro che soffrono di gravi perdite uditive.
Envoy Medical (NASDAQ: COCH), una empresa de salud auditiva que se especializa en sistemas auditivos completamente implantados, ha recibido una nueva patente (No. 12,081,061) para su Sistema de Recarga para Baterías Implantables. La patente, emitida el 3 de septiembre, se refiere a la predicción y gestión de la dosis térmica durante la carga de la batería, asegurando temperaturas seguras para las baterías recargables implantadas.
Esta tecnología ajusta la corriente proporcionada al dispositivo durante la carga, manteniendo la seguridad para los pacientes con dispositivos médicos implantados. El CEO Brent Lucas destacó la importancia de esta innovación en la mitigación de riesgos para los dispositivos implantados, describiéndola como una solución eficaz para sus productos. La patente se suma a la creciente cartera de Envoy Medical, avanzando en su misión de desarrollar dispositivos completamente implantados para aquellos con pérdida auditiva significativa.
Envoy Medical (NASDAQ: COCH)는 완전 이식형 청각 시스템을 전문으로 하는 청각 건강 회사로, 이식 가능 배터리용 충전 시스템에 대한 새로운 특허(번호 12,081,061)를 받았습니다. 9월 3일에 발급된 이 특허는 충전 중 배터리의 열량을 예측하고 관리하는 것과 관련이 있으며, 이식된 리튬 이온 배터리의 안전한 온도를 보장합니다.
이 기술은 충전 중 장치에 제공되는 전류를 조정하여 이식된 의료 장치가 있는 환자의 안전을 유지합니다. CEO인 브렌트 루카스는 이 혁신이 이식 장치의 위험을 완화하는 데 얼마나 중요한지 강조하며, 이를 자사 제품을 위한 효과적인 솔루션으로 설명했습니다. 이 특허는 Envoy Medical의 성장하는 포트폴리오에 추가되어, 심각한 청력 상실이 있는 사람들을 위해 완전 이식형 장치를 개발하려는 그들의 사명을 더욱 발전시킵니다.
Envoy Medical (NASDAQ: COCH), une entreprise de santé auditive spécialisée dans les systèmes auditifs entièrement implantés, a obtenu un nouveau brevet (No. 12,081,061) pour son Système de Recharge pour Batteries Implantables. Le brevet, délivré le 3 septembre, concerne la prédiction et la gestion de la dose thermique lors de la charge de la batterie, garantissant des températures sûres pour les batteries rechargeables implantées.
Cette technologie ajuste le courant fourni au dispositif pendant la charge, maintenant la sécurité pour les patients ayant des dispositifs médicaux implantés. Le PDG Brent Lucas a souligné l'importance de cette innovation pour la mitigation des risques liés aux dispositifs implantés, la qualifiant de solution efficace pour leurs produits. Le brevet s'ajoute au portefeuille croissant d'Envoy Medical, faisant progresser leur mission de développer des dispositifs entièrement implantés pour les personnes souffrant d'une perte auditive significative.
Envoy Medical (NASDAQ: COCH), ein Unternehmen, das sich auf Hörgesundheit und vollständig implantierbare Hörsysteme spezialisiert hat, wurde ein neues Patent (Nr. 12,081,061) für sein Nachladesystem für implantierbare Batterien erteilt. Das Patent, das am 3. September ausgestellt wurde, bezieht sich auf die Vorhersage und das Management der thermischen Dosis während des Ladevorgangs und gewährleistet sichere Temperaturen für implantierte wiederaufladbare Batterien.
Diese Technologie passt den Strom an, der während des Ladevorgangs an das Gerät geliefert wird, und sorgt für die Sicherheit von Patienten mit implantierten medizinischen Geräten. CEO Brent Lucas betonte die Bedeutung dieser Innovation zur Risikominderung für implantierte Geräte und bezeichnete sie als effektive Lösung für ihre Produkte. Das Patent erweitert das wachsende Portfolio von Envoy Medical und fördert deren Mission, vollständig implantierte Geräte für Menschen mit erheblichem Hörverlust zu entwickeln.
- Awarded new patent for Recharge System for Implantable Battery
- Technology ensures safe temperatures during battery recharging for implanted devices
- Expanding patent portfolio strengthens company's position in fully implanted hearing systems
- None.
This patent for a recharge system in implantable batteries marks a significant advancement in hearing implant technology. The innovative approach to predicting cumulative thermal dose during charging addresses a critical safety concern in implantable devices. By adjusting current provision to maintain safe temperatures, Envoy Medical has potentially solved a key challenge in long-term implant viability.
This technology could extend battery life and reduce the frequency of surgical interventions for battery replacement, greatly improving patient quality of life. Moreover, it positions Envoy Medical as a leader in implantable hearing solutions, potentially opening doors to applications in other medical fields requiring long-term implants. The patent strengthens the company's competitive edge and could lead to increased market share in the growing hearing health sector.
Envoy Medical's new patent strengthens its intellectual property portfolio, potentially enhancing its market position and valuation. While the immediate financial impact may be , the long-term implications are promising. This technology could:
- Reduce liability risks associated with implant complications
- Increase product differentiation, possibly leading to premium pricing
- Attract partnerships or licensing opportunities
Investors should note that while patents are valuable assets, their true worth lies in successful commercialization. Envoy Medical's ability to translate this innovation into market-ready products and revenue growth will be crucial. The company's NASDAQ listing ("COCH") may see positive sentiment, but substantial financial benefits will likely materialize in the medium to long term as the technology is integrated into product lines.
Growing Portfolio of Patents Further Advances the Company’s Mission to Develop Fully Implanted Devices for Those Suffering from Significant Hearing Loss
WHITE BEAR LAKE, Minnesota, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announces it has been awarded another patent from the US Patent & Trademark Office for its fully implanted devices. On September 3rd, the Company was issued Patent No. 12,081,061, “Recharge System for Implantable Battery,” which relates to predicting a cumulative thermal dose associated with charging an implantable rechargeable energy storage device to a fully charged state and adjusting the amount of current provided to the device during charging. In other words, this can be used to maintain a safe temperature of an implanted rechargeable battery during recharging.
“We are pleased to continue to add to our growing portfolio of patents as we further develop our innovative technologies,” said Envoy Medical CEO Brent Lucas. “Maintaining safe battery temperatures during recharging is an important risk mitigation for any implanted medical device, and we believe we have patented an effective solution for our products.”
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear’s natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can’t lose it. You don’t clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant (“Acclaim CI”) will be a first-of-its-kind fully implanted cochlear implant. Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019. We believe the Acclaim CI was the first hearing-focused device to receive Breakthrough Device Designation.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the benefits of intellectual property developed by Envoy; the potential for passage of legislation related to reimbursement for active middle ear hearing devices; the impact that such proposed legislation might have on the hearing health market, reimbursement for the Esteem FI-AMEI device, and the Envoy Medical business, and future market conditions or economic performance, as well as any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical’s Class A Common Stock; changes in or removal of Envoy Medical’s shares inclusion in any index; Envoy Medical’s success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical’s suppliers, or disruptions in Envoy Medical’s own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical’s key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” in the Annual Report on Form 10-K filed by Envoy Medical on April 1, 2024, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical’s good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
###
Investor Contact:
CORE IR
516-222-2560
investorrelations@envoymedical.com
FAQ
What new patent has Envoy Medical (COCH) been awarded in September 2024?
How does Envoy Medical's new patented technology work for implantable batteries?
What is the significance of Envoy Medical's new patent for their hearing health products?
When was Envoy Medical (COCH) awarded the patent for their Recharge System for Implantable Battery?
